# EDGAR Filing Document

**Accession Number:** 0001837493
**File Stem:** 0001213900-25-061642
**Filing Date:** 2025-7
**Character Count:** 9919
**Document Hash:** 25e34f7600bd12c09abb5bb643dd420e
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-25-061642.hdr.sgml**: 20250707

**ACCESSION NUMBER**: 0001213900-25-061642

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 3

**CONFORMED PERIOD OF REPORT**: 20250707

**FILED AS OF DATE**: 20250707

**DATE AS OF CHANGE**: 20250707

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Inspira Technologies OXY B.H.N. Ltd
- **CENTRAL INDEX KEY:** 0001837493
- **STANDARD INDUSTRIAL CLASSIFICATION:** SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 000000000
- **STATE OF INCORPORATION:** L3
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40303
- **FILM NUMBER:** 251107068

**BUSINESS ADDRESS:**
- **STREET 1:** HATIDHAR 2
- **STREET 2:** 11TH FLOOR
- **CITY:** RA'ANANA
- **STATE:** L3
- **ZIP:** 4366504
- **BUSINESS PHONE:** 972-9-9664488

**MAIL ADDRESS:**
- **STREET 1:** HATIDHAR 2
- **STREET 2:** 11TH FLOOR
- **CITY:** RA'ANANA
- **STATE:** L3
- **ZIP:** 4366504

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER**

**PURSUANT TO RULE 13a-16 OR 15d-16**

**UNDER THE SECURITIES EXCHANGE ACT OF 1934**

**For the Month of July 2025 (Report No. 3)**

**Commission File Number: 001-40303**

**Inspira Technologies Oxy B.H.N. Ltd.**

**(Translation of registrant's name into English)**

**2 Ha-Tidhar St.**

**Ra'anana 4366504, Israel**

**(Address of principal executive office)**

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

☒ Form 20-F ☐ Form 40-F

**<u>CONTENTS</u>**

On July 7, 2025, Inspira Technologies Oxy B.H.N. Ltd., or the Registrant, issued a press release titled "Inspira in High-Level Government Talks to Advance National Integration of the ART100 and Establish a Global Distribution Framework," a copy of which is furnished as Exhibit 99.1 with this report of foreign private issuer on Form 6-K.

The first three paragraphs and the section titled "Forward-Looking Statements" in the press release are incorporated by reference into the Registrant's Registration Statements on Form F-3 (Registration Nos. [333-266748](https://www.sec.gov/Archives/edgar/data/1837493/000121390022046430/ea164081-f3_inspiratech.htm) and [333-284308](https://www.sec.gov/Archives/edgar/data/1837493/000121390025004023/ea0227763-f3_inspira.htm)) and Form S-8 (Registration Nos. [333-259057](https://www.sec.gov/Archives/edgar/data/1837493/000121390021044780/ea146415-s8_inspiratech.htm), [333-277980](https://www.sec.gov/Archives/edgar/data/1837493/000121390024023044/ea0201791-s8_inspira.htm) and [333-285565](http://www.sec.gov/Archives/edgar/data/1837493/000121390025020699/ea0233153-s8_inspira.htm)), filed with the Securities and Exchange Commission, to be a part thereof from the date on which this Report of Foreign Private Issuer on Form 6-K is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

---

| | |
|:---|:---|
| **Exhibit No.** |  |
| 99.1 | [Press Release issued by Inspira Technologies Oxy B.H.N. Ltd. on July 7, 2025, titled "Inspira in High-Level Government Talks to Advance National Integration of the ART100 and Establish a Global Distribution Framework"](ea024825901ex99-1_inspira.htm) |

---

**<u>SIGNATURES</u>**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | | |
|:---|:---|:---|:---|
|  | **Inspira Technologies Oxy B.H.N. Ltd.** | **Inspira Technologies Oxy B.H.N. Ltd.** | **Inspira Technologies Oxy B.H.N. Ltd.** |
| Date: July 7, 2025 | By: | /s/ Dagi Ben-Noon | /s/ Dagi Ben-Noon |
|  |  | Name: | Dagi Ben-Noon |
|  |  | Title: | Chief Executive Officer |

---

## Exhibit 99.1

**Exhibit 99.1**

![](ex99-1_001.jpg)

**Inspira in High-Level Government Talks to Advance National Integration of<br> the ART100 and Establish a Global Distribution Framework**

RA'ANANA, Israel, July 7, 2025 -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) ("**Inspira,**" **"Inspira Technologies**," or the "**Company**"), a pioneer in innovative life-support and diagnostic technologies, today announced that it is engaged in high-level talks with a government health authority, located outside of the United States, which are intended to advance the national integration of its FDA-cleared ART100 system as a foundational component of the national emergency infrastructure and to establish a global distribution framework.

The meeting, scheduled for July 8, 2025, is intended to define the key terms and roadmap for this strategic collaboration. These advanced discussions were initiated following a direct invitation from the government of the health authority, which is actively seeking to secure next-generation medical technologies and enhance national emergency readiness.

The government involved is recognized for its extensive commercial ties and diplomatic channels spanning the entire international community. Accordingly, the agenda will also feature the discussion relating to the establishment of a global distribution framework that leverages these unique capabilities with the aim to accelerate and increase the profitability of the $22.5 million purchase order received by Inspira, as announced on July 2, 2025.

Dagi Ben-Noon, CEO of Inspira Technologies, stated: "Engaging in strategic dialogue with national leadership is an important milestone for us and that it reflects the growing recognition that the ART100 is more than a medical device, but rather a vital tool for national preparedness. In parallel, we intend to leverage the government's international reach to build a global distribution engine that is intended to maximize the profitability of our recent deal and those to come".

This high-level discussions marks a significant validation and acceleration of Inspira's stated strategy, signaling a fundamental shift from regional commercial deals to global, government-level partnerships.

**About Inspira Technologies**

Inspira Technologies is a commercial-stage medical device company specializing in advanced respiratory support and real-time blood monitoring solutions. The Company's U.S. Food and Drug Administration -cleared INSPIRA™ ART100 system is approved for cardiopulmonary bypass in the U.S. and ECMO (Extracorporeal Membrane Oxygenation) procedures outside the U.S and serves as a foundation for the development of the INSPIRA ART500 — a next-generation system designed to deliver oxygenation while patients remain awake and spontaneously breathing. Inspira Technologies is also advancing HYLA™, a proprietary blood sensor platform offering continuous, non-invasive monitoring. With multiple cleared products, a growing IP portfolio, and strategic streamlining of its operations, Inspira Technologies is increasingly positioned as an attractive platform within the life-support and MedTech landscape. The Company's recent internal shifts may reflect broader alignment with long-term industry trends, including consolidation, cross-sector collaboration, and potential strategic partnerships. For more information, visit: https://inspira-technologies.com

**Forward-Looking Statement Disclaimer**

This press release contains express or implied forward-looking statements pursuant to U.S. Federal securities laws. These forward-looking statements are based on the current expectations of the management of the Company only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. For example, the Company is using forward-looking statements when it discusses the expected timing and nature of the meeting with the government health authority with which it is holding discussions, including the intended role of the ART100 system in the national emergency infrastructure and global distribution framework vision, the anticipated increased profitability of the Company should it be able to leverage its recent purchase order, the belief that engaging in strategic dialogue with national leadership is an important milestone for the Company and that it reflects the growing recognition that the ART100 is a vital tool for national preparedness, the Company's intention to leverage the government's international reach to build a global distribution engine that will maximize the profitability of the Company's recent purchase order, and the belief that these discussions mark a significant validation and acceleration of the Company's stated strategy, signaling a fundamental shift from regional commercial deals to global, government-level partnerships. These forward-looking statements and their implications are based solely on the current expectations of the Company's management and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Except as otherwise required by law, the Company undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. More detailed information about the risks and uncertainties affecting the Company is contained under the heading "Risk Factors" in the Company's annual report on Form 20-F for the fiscal year ended December 31, 2024, filed with the U.S. Securities and Exchange Commission (the "SEC"), which is available on the SEC's website at www.sec.gov.

**Company Contact**<br> Inspira Technologies – Media Relations<br> Email: info@inspirao2.com<br> Phone: +972-9-9664485